Biomarkers of AAA Progression. Part 1: Extracellular Matrix Degeneration

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2009 May 27

PMID 19468292

Citations 69

Authors

Femke A M V I Hellenthal

Willem A Buurman

Will K W H Wodzig

Geert Willem H Schurink

Affiliations

Soon will be listed here.

Abstract

Abdominal aortic aneurysm (AAA) is an important health problem. Elective surgical treatment is recommended on the basis of an individual's risk of rupture, which is predicted by AAA diameter. However, the natural history of AAA differs between patients and a reliable and individual predictor of AAA progression (growth and expansion rates) has not been established. Several circulating biomarkers are candidates for an AAA diagnostic tool. However, they have yet to meet the triad of biomarker criteria: biological plausibility, correlation with AAA progression, and prediction of treatment effect on disease outcome. Circulating levels of markers of extracellular matrix degeneration, such as elastin peptides, aminoterminal propeptide of type III procollagen, elastase-alpha1-antitrypsin complexes, matrix metalloproteinase 9, cystatin C, plasmin-antiplasmin complexes and tissue plasminogen activator, have been correlated with AAA progression and have biological plausibility. Although studies of these markers have shown promising results, they have not yet led to a clinically applicable biomarker. In future studies, adjustment for initial AAA size, smoking history and the measurement error for determination of AAA size, among other variables, should be taken into account. A large, prospective, standardized, follow-up study will be needed to investigate multiple circulating biomarkers for their potential role in the prediction of AAA progression, followed by a study to investigate the effect of treatment on the circulating levels of biomarkers.

Citing Articles

Inhibition of Abdominal Aortic Aneurysm Progression Through the CXCL12/CXCR4 Axis via MiR206-3p Sponge.

Xuan X, Li Y, Cao G, Hu J, Yan S, Jin H J Cell Mol Med. 2025; 29(1):e70328.

PMID: 39779470 PMC: 11710933. DOI: 10.1111/jcmm.70328.

Vinpocetine alleviates the abdominal aortic aneurysm progression via VSMCs SIRT1-p21 signaling pathway.

Yang H, Li Z, Dong X, Zhang J, Shan J, Wang M Acta Pharmacol Sin. 2024; 46(1):96-106.

PMID: 39179867 PMC: 11696035. DOI: 10.1038/s41401-024-01358-w.

Pharmacological Inhibition of MMP-12 Exerts Protective Effects on Angiotensin II-Induced Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice.

Di Gregoli K, Atkinson G, Williams H, George S, Johnson J Int J Mol Sci. 2024; 25(11).

PMID: 38891996 PMC: 11172660. DOI: 10.3390/ijms25115809.

Diagnostic Utility of a Combined MPO/D-Dimer Score to Distinguish Abdominal Aortic Aneurysm from Peripheral Artery Disease.

Zagrapan B, Klopf J, Celem N, Brandau A, Rossi P, Gordeeva Y J Clin Med. 2023; 12(24).

PMID: 38137627 PMC: 10743483. DOI: 10.3390/jcm12247558.

Association of Genetic Polymorphisms with Abdominal Aortic Aneurysm in the Processes of Apoptosis, Inflammation, and Cholesterol Metabolism.

Nugroho N, Herten M, Torsello G, Osada N, Marchiori E, Sielker S Medicina (Kaunas). 2023; 59(10).

PMID: 37893562 PMC: 10608078. DOI: 10.3390/medicina59101844.

References

Curci J, Liao S, Huffman M, Shapiro S, Thompson R . Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest. 1998; 102(11):1900-10. PMC: 509141. DOI: 10.1172/JCI2182. View

Miller Jr F . Aortic aneurysms: It's all about the stress. Arterioscler Thromb Vasc Biol. 2002; 22(12):1948-9. DOI: 10.1161/01.atv.0000047947.37203.82. View

Kolbel T, Strandberg K, Mattiasson I, Stenflo J, Lindblad B . Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. J Vasc Surg. 2006; 43(5):935-9. DOI: 10.1016/j.jvs.2006.01.019. View

Holmes D, Liao S, Parks W, Thompson R . Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg. 1995; 21(5):761-71; discussion 771-2. DOI: 10.1016/s0741-5214(05)80007-2. View

Satta J, Haukipuro K, Kairaluoma M, Juvonen T . Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. J Vasc Surg. 1997; 25(5):909-15. DOI: 10.1016/s0741-5214(97)70222-2. View

Liu J, Sukhova G, Sun J, Xu W, Libby P, Shi G . Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24(8):1359-66. DOI: 10.1161/01.ATV.0000134530.27208.41. View

Sakalihasan N, Limet R, Defawe O . Abdominal aortic aneurysm. Lancet. 2005; 365(9470):1577-89. DOI: 10.1016/S0140-6736(05)66459-8. View

Lindholt J, Ashton H, Heickendorff L, Scott R . Serum elastin peptides in the preoperative evaluation of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2001; 22(6):546-50. DOI: 10.1053/ejvs.2001.1516. View

Newman K, Ogata Y, Malon A, Irizarry E, Gandhi R, Nagase H . Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb. 1994; 14(8):1315-20. DOI: 10.1161/01.atv.14.8.1315. View

10.

Freestone T, Turner R, Coady A, Higman D, Greenhalgh R, Powell J . Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995; 15(8):1145-51. DOI: 10.1161/01.atv.15.8.1145. View

11.

Libby P . Changing concepts of atherogenesis. J Intern Med. 2000; 247(3):349-58. DOI: 10.1046/j.1365-2796.2000.00654.x. View

12.

Lindholt J, Jorgensen B, Shi G, Henneberg E . Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003; 25(6):546-51. DOI: 10.1053/ejvs.2002.1872. View

13.

Chew D, Orshal J, Khalil R . Elastase promotes aortic dilation by inhibiting Ca2+ influx into vascular smooth muscle. J Cardiovasc Pharmacol. 2004; 43(4):504-13. DOI: 10.1097/00005344-200404000-00005. View

14.

Irizarry E, Newman K, Gandhi R, Nackman G, Halpern V, Wishner S . Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res. 1993; 54(6):571-4. DOI: 10.1006/jsre.1993.1087. View

15.

Lindholt J, Heickendorff L, Vammen S, Fasting H, Henneberg E . Five-year results of elastin and collagen markers as predictive tools in the management of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2001; 21(3):235-40. DOI: 10.1053/ejvs.2001.1329. View

16.

Sakalihasan N, Delvenne P, Nusgens B, Limet R, Lapiere C . Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg. 1996; 24(1):127-33. DOI: 10.1016/s0741-5214(96)70153-2. View

17.

. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet. 1998; 352(9141):1649-55. View

18.

Wilson K, Lindholt J, Hoskins P, Heickendorff L, Vammen S, Bradbury A . The relationship between abdominal aortic aneurysm distensibility and serum markers of elastin and collagen metabolism. Eur J Vasc Endovasc Surg. 2001; 21(2):175-8. DOI: 10.1053/ejvs.2001.1303. View

19.

Murphy G, Atkinson S, WARD R, Gavrilovic J, Reynolds J . The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci. 1992; 667:1-12. DOI: 10.1111/j.1749-6632.1992.tb51590.x. View

20.

Liu J, Sukhova G, Yang J, Sun J, Ma L, Ren A . Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2005; 184(2):302-11. DOI: 10.1016/j.atherosclerosis.2005.05.012. View